Report #2829769

Received Mar 5, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: NY
Recovered: Unknown
Vaccinated: Feb 13, 2025
Onset: Feb 22, 2025
Days to onset: 9
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEP	HEP B (HEPLISAV-B)	DYNAVAX TECHNOLOGIES CORPORATION	1	945660	IM / LA

Symptoms (2)

Inappropriate schedule of product administrationNo adverse event

Symptom narrative

Received First Dose , and Second Dose 9 Days Apart; Initial report received on 24-Feb-2025. A nurse reported that a 21-year-old female (race, ethnicity not reported) received the second dose of HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization 9 days after receiving the first dose. No medical history or concomitant medications were reported. On 13-Feb-2025, the patient received dose 1 of a hepatitis B vaccine [HEPLISAV-B (lot # 945660, expiration date 31-Jan-2025, NDC # 43528-0003-01) intramuscularly in the left deltoid. On 22-Feb-2025, 9 days after receiving after having been vaccinated with HEPLISAV-B, the patient received dose 2 of a hepatitis B vaccine [HEPLISAV-B (lot # 945660, expiration date 31-Jan-2027, NDC# 43528-003-01) intramuscularly in the left deltoid. No adverse effects were reported. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.